Document Type : Original Article(s)


1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Cardiac Rehabilitation Research Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor of Cardiology/Fellowship in Heart Failure and Transplantation, Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran


Background: It has been previously shown that Implantable Cardioverter-Defibrillator (ICD) shocks are associated with subsequent increased mortality risk in patients with heart failure. We designed this study to assess the factors related to ICD shocks in patients with ischemic cardiomyopathy (ICM).
Methods: Eighty consecutive patients with ICM underwent primary or secondary preventive ICD implantation, and experienced shocks were recruited in this cross-sectional study between March 2018 and March 2019. Patients were grouped based on the presence of appropriate or inappropriate ICD therapy. Data on demographic, clinical, laboratory and medications of eligible patients were assessed to identify ICD shocks related factors with univariate and multiple adjusted models.
Results: The mean age of the total population was 65.4 ± 9.8 years (males: 86.3%). Eleven patients (13.7%) experienced inappropriate shocks. The presence of sinus tachycardia was 7.38 (95% confidence interval (CI): 1.78-30.56, P= 0.006), which was associated with higher likelihood of inappropriate shock occurrence. Moreover, patients with atrial fibrillation (AF) had significantly elevated odds of inappropriate shock frequency (odds ratio (OR): 4.32, 95% CI: 1.15-16.13, P= 0.02).
Conclusion: Our findings indicate that the presence of sinus tachycardia and prior AF could significantly increase the likelihood of inappropriate shock frequency among patients with ICM using ICDs. Further large-scale studies are required to prove our outcomes.


  1. Ouellet G, Huang DT, Moss AJ, Hall WJ, Barsheshet A, McNitt S, Klein H, Zareba W, Goldenberg I. Effect of cardiac resynchronization therapy on the risk of first and recurrent ventricular tachyarrhythmic events in MADIT-CRT. J Am Coll Cardiol. 2012; 60(18):1809-16.
  2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37:2129-200.
  3. Yancy CW, Jessup M, Bozkurt B, Butler J, CaseyJr DE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation. 2013;28(16):e240-327.
  4. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933-40.
  5. Dichtl W, Wolber T, Paoli U, Brullmann S, Stuhlinger M, Berger T, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter-defibrillator patients. Clin Cardiol. 2011;34:433-436.
  6. van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556-562.
  7. Kleemann T, Hochadel M, Strauss M, Skarlos A, Seidl K, Zahn R. Comparison between atrial fibrillation-triggered implantable cardioverterdefibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice. J Cardiovasc Electrophysiol. 2012; 23(7):735-40.
  8. Gracieux J, Sanders GD, Pokorney SD, Lopes RD, Thomas K, Al-Khatib SM. Incidence and predictors of appropriate therapies delivered by the implantable cardioverter-defibrillator in patients with ischemic cardiomyopathy: a systematic review. Int J Cardiol. 2014;177(3):990-4.
  9. Sood N, Ruwald AC, Solomon S, Daubert JP, McNitt S, Polonsky B, et al. Association between a myocardial substrate, implantable cardioverterdefibrillator shocks and mortality in MADIT-CRT. Eur Heart J. 2014;35(2):106-15.
  10. Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, et al. Hemodynamic deterioration during ICD implant: predictors of highrisk patients. Am Heart J. 1994;127(4 Pt 2):1064-7.
  11. Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210- 8.
  12. Landmesser U, Drexler H. Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Pract Cardiovasc Med. 2005;2(12):628-38.
  13. Mustafa U, Dherange P, Reddy R, DeVillier J, Chong J, Ihsan A, et al. Atrial Fibrillation Is Associated With Higher Overall Mortality in Patients With Implantable Cardioverter‐Defibrillator: A Systematic Review and Meta‐Analysis. J Am Heart Assoc. 2018;7(22):e010156.
  14. Desai H, Aronow WS, Ahn C, Gandhi K, Hussain S, Lai HM, Sharma M, Frishman WH, Cohen M, Sorbera C. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverterdefibrillator shocks, and time to mortality in 549 patients with heart failure. The American journal of cardiology. 2010;105(9):1336-8.
  15. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51(14):1357-65.
  16. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012; 367(24):2275-83.
  17. Kutyifa V, Moss AJ, Schuger C, McNitt S, Polonsky B, Ruwald ACH, Ruwald MH, Daubert JP, Zareba W. Reduction in inappropriate ICD therapy in MADIT-RIT patients without history of atrial tachyarrhythmia. J Cardiovasc Electrophysiol. 2015; 26(8):879-84.
  18. Kosiuk J, Nedios S, Darma A, Rolf S, Richter S, Arya A, et al. Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2014;16(9):1322-6.
  19. Hori M, Okamoto H. Heart rate as a target of the treatment of chronic heart failure. J Cardiol. 2012;60(2):86-90.

20.Ruwald MH, Abu-Zeitone A, Jons C, Ruwald AC, McNitt S, Kutyifa V, et al. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADITCRT trial (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2013;62(15):1343- 50.

  1. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2006;114(25):2766-72.
  2. Raitt MH. Inappropriate implantable defibrillator shocks: an adverse outcome that can be prevented. J Am Coll Cardiol. 2013 Oct 8;62(15):1351-2.
  3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.
  4. Ghavami Ghanbarabadi V, Jamali J, HeidariBakavoli A, Tayyebi M, Nazari Hyanlo H, Shakeri MT. Factors influencing the status of appropriate and inappropriate shocks delivered by an implantable cardioverter defibrillator. J Birjand Univ Med Sci. 2013;20(1):94-101.
  5. Bansal N, Szpiro A, Masoudi F, Greenlee RT, Smith DH, Magid DJ, et al. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. Heart. 2017;103(7):529-37.
  6. Tzeis S, Andrikopoulos G, Kolb C, Vardas PE. Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks. Europace. 2008;10(11):1256-65.